De Novo Design, Synthesis, In Silico, and Anticancer Studies of N α ‐Fmoc/Cbz‐Amino Acid Derived 2‐Amino‐1,3,4‐thiadiazines
ChemistrySelect · 2026-11 · 11 (41)
DOI: 10.1002/slct.75034 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemistrySelect, online erschienen am 03.11.2026. Verfasst von Ramya M und 5 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben.
Abstract (Originalsprache)
The present work reveals an optimized protocol for the synthesis of novel six‐membered 2‐amino‐1,3,4‐thiadiazine derivatives of N α ‐protected amino acids, using N α ‐Fmoc/Cbz‐amino acid‐derived bromoketone in conjunction with thiosemicarbazide. In silico studies highlighted promising interactions for the anticancer proteins EGFR and MMP‐9 of 10 compounds (4a–4j) synthesized. Compound 4e showed a significant docking score of −8.4 kcal/mol and compound 4j scored −7.9 kcal/mol for EGFR. Additionally, compound 4e exhibited a strong binding affinity of −9.2 kcal/mol, and compound 4j scored −8.7 kcal/mol for MMP‐9. Overall, the synthesized 2‐amino‐1,3,4‐thiadiazines (4a–4j) demonstrate encouraging interactions for potential cancer therapy.
Zitieren
APA
M, R., Vhanmane, V. R., B, K., Sanaga, N., Veladi, P., & G, N. (2026). De Novo Design, Synthesis, In Silico, and Anticancer Studies of N α ‐Fmoc/Cbz‐Amino Acid Derived 2‐Amino‐1,3,4‐thiadiazines. ChemistrySelect, 11(41). https://doi.org/10.1002/slct.75034
Vancouver
M R, Vhanmane VR, B K, Sanaga N, Veladi P, G N. De Novo Design, Synthesis, In Silico, and Anticancer Studies of N α ‐Fmoc/Cbz‐Amino Acid Derived 2‐Amino‐1,3,4‐thiadiazines. ChemistrySelect. 2026;11(41). doi:10.1002/slct.75034
BibTeX
@article{M2026,
author = {M, Ramya and Vhanmane, Vaishnavi R. and B, Kirankumar and Sanaga, Narayana and Veladi, Panduranga and G, Nagendra},
title = {De Novo Design, Synthesis, In Silico, and Anticancer Studies of N α ‐Fmoc/Cbz‐Amino Acid Derived 2‐Amino‐1,3,4‐thiadiazines},
journal = {ChemistrySelect},
year = {2026},
volume = {11},
number = {41},
doi = {10.1002/slct.75034}
}
EUVIMED